Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price

SPROStock

$1.10−53.19%52W

Market Cap$64.06M

P/E7.47x

PEG Ratio—

Div yield—

Beta1.54

SPRO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-70.34%

Price vs S&P 500 (4W)-2.18%

VGM Score53.50

P/E Ratio (Annual)7.47x

Book Value / Share (Quarterly)$0.76

P/TBV (Annual)0.83x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)7.68%

Cash Flow / Share (Quarterly)$0.34

Price vs S&P 500 (YTD)-64.72%

Net Profit Margin (TTM)24.90%

EPS (TTM)$0.04

10-Day Avg Trading Volume0.47M

EPS Excl Extra (TTM)$0.04

Revenue Growth (5Y)48.25%

EPS (Annual)$0.15

ROI (Annual)14.52%

Net Profit Margin (5Y Avg)-137.28%

Cash / Share (Quarterly)$0.87

P/E Basic Excl Extra (TTM)8.68x

Revenue Growth QoQ (YoY)-95.61%

P/E Normalized (Annual)7.47x

ROA (Last FY)12.44%

Revenue Growth TTM (YoY)-3.25%

EBITD / Share (TTM)$0.10

ROE (5Y Avg)-55.12%

Operating Margin (TTM)22.08%

Cash Flow / Share (Annual)$-0.22

P/B Ratio1.45x

P/B Ratio (Quarterly)2.89x

Net Income / Employee (Annual)$342,900

EV / Revenue (TTM)0.22x

Net Interest Coverage (TTM)-79.03x

ROA (TTM)12.57%

EV / EBITDA (TTM)2.20x

EPS Incl Extra (Annual)$0.15

Current Ratio (Annual)7.59x

Quick Ratio (Quarterly)6.03x

3-Month Avg Trading Volume1.26M

52-Week Price Return-53.19%

P/E Incl Extra (TTM)8.68x

Revenue / Employee (TTM)$1,879,900

Tangible BV / Share (Quarterly)$1.01

P/S Ratio (Annual)0.96x

Asset Turnover (Annual)0.97x

52-Week High$3.08

Operating Margin (5Y Avg)-138.01%

EPS Excl Extra (Annual)$0.15

Tangible BV CAGR (5Y)-2.14%

26-Week Price Return-60.43%

Quick Ratio (Annual)7.40x

13-Week Price Return-30.38%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.12x

Enterprise Value$13.28M

Revenue / Share Growth (5Y)22.11%

Asset Turnover (TTM)1.00x

Book Value / Share Growth (5Y)-25.34%

Revenue / Employee (Annual)$2,672,100

Pretax Margin (Annual)13.22%

Cash / Share (Annual)$0.71

3-Month Return Std Dev61.42%

Net Income / Employee (TTM)$295,300

ROE (Last FY)14.52%

Net Interest Coverage (Annual)-52.52x

EPS Basic Excl Extra (Annual)$0.15

P/FCF (TTM)1.92x

Receivables Turnover (TTM)7.37x

EV / Free Cash Flow (TTM)0.68x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.04

Receivables Turnover (Annual)28.73x

ROI (TTM)16.17%

P/S Ratio (TTM)1.05x

Pretax Margin (5Y Avg)-136.71%

Revenue / Share (Annual)$1.13

Tangible BV / Share (Annual)$1.45

Forward P/E7.77x

Price vs S&P 500 (52W)-68.72%

P/E Ratio (TTM)8.68x

Year-to-Date Return-52.79%

5-Day Price Return-6.78%

EPS Normalized (Annual)$0.15

ROA (5Y Avg)-25.35%

Net Profit Margin (Annual)12.83%

Month-to-Date Return-9.09%

Cash Flow / Share (TTM)$-0.02

EBITD / Share (Annual)$0.11

Operating Margin (Annual)9.45%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)3.27x

ROI (5Y Avg)-47.92%

P/E Excl Extra (TTM)8.68x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.04

P/TBV (Quarterly)1.17x

P/B Ratio (Annual)2.22x

Pretax Margin (TTM)25.33%

Book Value / Share (Annual)$1.05

Price vs S&P 500 (13W)-33.07%

Beta1.54x

Revenue / Share (TTM)$0.81

ROE (TTM)16.17%

52-Week Low$1.08

vGradeA

gGradeC

mGradeD

vgmGradeC

SPRO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	—	-$0.16	—
Q3 2025	Nov 13, 2025	-$0.25	-$0.13	+48.00%(+$0.12)
Q2 2025	Aug 12, 2025	-$0.38	-$0.03	+92.11%(+$0.35)
Q1 2025	May 13, 2025	-$0.44	-$0.25	+43.81%(+$0.19)

SPRO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SPROSpero Therapeutics, Inc. Common Stock	A	C	D	1.0x	-3.3%	—	—	$1.10
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Spero Therapeutics, Inc. Common Stock

Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel antibiotics for multi-drug-resistant bacterial infections and rare diseases. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic for MDR Gram-negative infections; SPR720 for non-tuberculous mycobacterial infections; and SPR206, an intravenous polymyxin candidate for hospital-acquired MDR Gram-negative infections.

SPRO Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeAMC

Revenue estimate$0

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

OKYOOKYO Pharma Limited Ordinary SharesBiological Products
CRDFCardiff Oncology, Inc. Common StockBiological Products
CGTXCognition Therapeutics, Inc. Common StockBiological Products
CSBRChampions Oncology, Inc.Biological Products
SLSNSolesence, Inc. Common StockCosmetics & Toiletries
CITRCitroTech Inc.Chemicals
ZTEKZentek Ltd. Common StockIndustrial Chemicals
LNZALanzaTech Global, Inc. Common StockIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

2.2

Sell

Consensus rating

52-Week Range

Low$1.08

High$3.08